Bulletin of Environment, Pharmacology and Life Sciences
Bull. Env. Pharmacol. Life Sci., Vol 13 [1] December 2023 :308-315

Online ISSN 2277-1808
Journal's URL:http://www.bepls.com
CODEN: BEPLAD

REVIEW ARTICLE **OPEN ACCESS**

From Code to Cure: Advancing Drug Discovery with Computer-Aided Design

Saurabh Dhumane[1], Tejas Naik[2*], Mahesh Shelke[2], Kiran Dukare[2], Krushna Dhongade[2]
Assistant Professor, Department of Pharmaceutical Analysis, Samarth College of Pharmacy, Belhe, Pune, Maharashtra, India.
Department of Pharmacy, Samarth College of Pharmacy, Belhe, Pune, Maharashtra, India.
Corresponding Author's Email: ntejas134@gmail.com

ABSTRACT
A multidisciplinary field that combines computational science, chemistry, biology, and informatics is known as computer-aided drug design. By utilizing computational tools and techniques to improve the identification of new drug candidates, it has transformed the process of drug discovery and development. This abstract provides an overview of the key aspects and contributions of CADD.CADD integrates a wide range of computational methods, including molecular modeling, virtual screening, molecular dynamics simulations, machine learning, and data mining, to predict and optimize interactions between drug molecules and their biological targets. Through these approaches, researchers gain insights into the three-dimensional structures, energetics, and dynamic behaviors of molecules, allowing for a rational and systematic approach to drug design. CADD has had a significant impact on the pharmaceutical industry. The time and money needed for drug development have been significantly decreased, drug candidate success rates have increased, and it has made it easier to create more specialized and individualized treatments. By understanding the molecular mechanisms of diseases and drug-target interactions, CADD has created new prospects for medicinal innovation.
KEYWORDS: Computer-Aided Drug Design, Computational Method, Molecular Modeling, Drug Discovery, Drug Design, QSAR, Structure-Based Drug Design

Received 15.10.2023 Revised 27.11.2023 Accepted 28.12.2023

INTRODUCTION

Computer-aided drug discovery (CADD) is a field of science that uses computational methods to identify and develop new drug candidates. CADD can be used to accelerate all stages of the drug discovery process, from identifying new drug targets to optimizing the properties of lead compounds. CADD methods are based on a variety of scientific disciplines, including chemistry, physics, biology, and computer science. Some of the most common CADD methods include CADD has become an essential tool in the drug discovery process.(1) By using CADD methods, researchers can identify and develop new drug candidates more quickly and efficiently than ever before. CADD can help to reduce the time and cost of drug discovery by identifying promising drug candidates early in the process. CADD can help to improve the success rates of drug discovery by identifying drug candidates that are more likely to be active and safe.(2) CADD can help to identify new drug targets that were previously unknown. CADD can be used to develop personalized medicines to the individual needs of each patient. CADD is a rapidly growing field, and new methods and technologies are being developed all the time.(3) CADD is playing an increasingly important role in the discovery and development of new drugs to treat a wide range of diseases.(4)

LIGAND-BASED DRUG DESIGN (LBDD)

Ligand-Based Drug Design is a fundamental approach in the field of drug discovery that involves the design and optimization of pharmaceutical compounds based on the properties and characteristics of known biologically active molecules, called ligands.(5) This method is particularly valuable when detailed structural information about the target biomolecule, such as a protein or enzyme, is limited.(6) LBDD relies on the premise that molecules with similar structures and physicochemical properties often exhibit similar biological activities, making it possible to design new drugs or improve existing ones.(7)

The first step in the LBDD process is data collecting and curation. Data about ligands and their characteristics may be found in the scientific literature, databases, and experimental investigations by researchers. This data contains information that is significant include the ligands chemical structure, the

target's affinity for them, and pharmacological characteristics. Data curation is a crucial step in this process.(8) This ensures that the data used for subsequent analysis is accurate and consistent. To efficiently manage and access the collected data, many drug discovery teams create specialized databases.(9) . These databases serve as repositories for knowledge that can be utilized in the drug design process. Before data analysis can commence, the collected information may undergo preprocessing. (10) This prepares the data for computational techniques by, for example, converting chemical structures into a standardized format, such as Simplified Molecular Input Line Entry System (SMILES) notation. Additionally, molecular descriptors, which are numerical representations of molecular properties (e.g., size, shape, and chemical functionality), may be calculated. These descriptors are invaluable for subsequent similarity analysis and quantitative structure-activity relationship (QSAR) modeling.(11)

Molecular similarity is a fundamental concept in LBDD and plays a crucial role in the process of identifying potential drug candidates and optimizing their properties.(12) At its core, molecular similarity refers to the degree of resemblance or likeness between two or more molecules based on their structural and chemical features. In LBDD, molecular similarity analysis is used to identify compounds that exhibit similarities to known biologically active molecules (ligands) and predict their potential pharmacological activities(13). One of the primary objectives of LBDD is to identify lead compounds—molecules that can serve as a starting point for drug development. Molecular similarity analysis helps molecules in large compound libraries or databases that closely resemble known active ligands.(14) The higher the similarity score, the greater the like that the candidate molecule shares similar biological activity. Molecular similarity analysis is indispensable in the search for analogs of known drugs or biologically active compounds.(15) Pharmacophores are abstract representations of the essential chemical features required for a ligand to interact with a specific target. Molecular similarity analysis can involve aligning the Pharmacophoric features of different molecules to assess their similarity.(16) Identifying compounds with matching pharmacophores is especially important in LBDD, as it ensures that potential drug candidates share the crucial structural features necessary for binding to the target biomolecule(17) Scaffold hopping refers to the process of identifying molecules with different core structures that exhibit similar biological activities to a reference compound. Molecular similarity analysis aids in scaffold hopping by highlighting compounds with comparable scaffold features.(18) This approach enables the exploration of diverse chemical space, potentially uncovering novel drug candidates with unique scaffolds and improved properties.(19)



Fig. 1. Rational Approach in Computer-Aided Drug Design (CADD)(25)

Quantitative approaches, such as QSAR modeling, use molecular similarity to predict the biological functions of unknown substances.(20) By comparing the structural characteristics of a molecule to those of known active ligands, QSAR models estimate its potential activity. This predictive capability is invaluable for prioritizing compounds for experimental testing, saving time and resources in the drug discovery process.(21) Molecular similarity is a key component of virtual screening. Computational algorithms

perform molecular docking simulations of ligands within the binding site of the target biomolecule.(22) Similarity-based scoring systems determine how likely ligands are to attach to the target. Molecular similarity-based virtual screening enables researchers to effectively select through significant chemical databases to find prospective therapeutic possibilities for testing purposes. Molecular similarity analysis can extend beyond pharmacological activity to assess toxicity and safety.(23) By comparing the structural features of compounds to known toxic molecules or identifying substructures associated with toxicity, LBDD can help identify compounds with potential safety concerns early in the drug discovery process.(24)

PHARMACOPHORE

Pharmacophore modeling is a crucial technique in the field of drug discovery and computer-aided drug design (CADD). In order for a molecule to interact with a particular biological target, such as a protein, enzyme, or receptor, it is necessary to build a three-dimensional (3D) representation of the chemical and structural properties. Pharmacophoric points are these characteristics, which are essential for the molecule's biological action.(26) Pharmacophore modeling plays a central role in the early stages of drug discovery and optimization by aiding in lead compound identification, virtual screening, and structure-based design.(27) Here's a closer look at the key aspects of pharmacophore modeling Feature points represent specific chemical features or functional groups essential for binding to the target. Common feature types include hydrogen bond donors and acceptors, hydrophobic regions, aromatic rings, positively or negatively charged groups, and more.(28) Pharmacophore models include information about the distances and angles between feature points. These physical limitations determine how the pharmacophore is arranged in three dimensions. ensuring that ligands must match both the chemical features and their relative positions.(29) In certain pharmacophore models, excluded volumes are also included. These volumes represent areas in space where ligands shouldn't interact sterically with the target or contain bulky groups.(30)

Generation of Pharmacophore Models:

Ligand-Based Pharmacophore Modeling: This approach relies on analyzing a set of known active ligands that bind to a specific target. By identifying common chemical features and their spatial arrangement in these ligands, a pharmacophore model is constructed. This method is especially useful when structural information about the target is limited.(31)

Structure-Based Pharmacophore Modeling: In cases where structural information about the target is available, pharmacophore models can be derived based on the interactions between the target and ligands. This approach is more target-specific and can provide insights into binding modes.(32)

Hybrid Pharmacophore Modeling: Hybrid models combine information from both ligand-based and structure-based methods to create more accurate and comprehensive pharmacophore models. This can improve the model's predictive power and applicability.(33)

Applications of Pharmacophore Modeling:

Pharmacophore models are used to screen compound libraries and identify molecules that match the Pharmacophoric features of known active ligands. This aids in the discovery of potential lead compounds for drug development. Once lead compounds are identified, pharmacophore modeling can guide the optimization process by suggesting structural modifications that maintain or enhance the ligand's fit to the pharmacophore.(34) Pharmacophore models are employed in virtual screening to assess the potential of a compound library to interact with the target. Compounds that fit the pharmacophore are prioritized for further experimental testing.(35) Pharmacophore models can be used to explore the potential of a drug candidate to interact with multiple targets, facilitating the development of multi-targeted therapies. Beyond binding to the target, pharmacophore models can incorporate features associated with toxicity or undesirable side effects, helping to identify compounds with improved safety profiles.(36) Generating accurate pharmacophore models requires reliable data and careful consideration of the relevant features, which can be challenging, especially for complex or poorly understood targets. (37) Balancing specificity with simplicity is essential to prevent false positives during virtual screening. Pharmacophore models are based on simplifications and assumptions about molecular interactions, and their accuracy depends on the quality of input data and the modeling approach used.(38)

QSAR:

QSAR analysis is a powerful and widely used computational technique in the field of drug discovery and chemical biology. QSAR analysis establishes quantitative relationships between the structural properties of chemical compounds and their biological or pharmacological activities.(39) This analytical approach plays a important role in predicting the activity of new compounds, optimizing lead compounds, and guiding the rational design of molecules with desired pharmacological properties.(40)

QSAR builds on the fundamental concept of SAR, which posits that the biological activity of a molecule is closely related to its chemical structure. SAR studies aim to understand how specific structural features influence a compound's activity. (41) Unlike qualitative SAR, which provides general insights into

structure-activity relationships, QSAR is quantitative. It establishes mathematical equations that quantify the relationship between structural descriptors and biological activities. QSAR analysis begins with the collection of data, including information on the chemical structures of compounds and their corresponding biological activities. (42) These data are usually gathered from experimental assays or databases. Molecular descriptors are numerical representations of a compound's structural and physicochemical properties. These descriptors can include molecular weight, lipophilicity (logP), electronegativity, and many others.(43) Computational tools are used to calculate these descriptors for each compound in the dataset. QSAR models are mathematical equations that relate the biological activity (dependent variable) to the calculated molecular descriptors (independent variables). (44) Various modeling techniques, such as multiple linear regression, partial least squares, or machine learning algorithms, are employed to establish these relationships. It's essential to validate QSAR models to ensure their predictive accuracy. Cross-validation, external validation, and other statistical tests are used to assess the model's performance. Once validated, QSAR models can be interpreted to identify which structural features or descriptors have the most significant impact on the biological activity. This information guides subsequent design and optimization efforts.(45)

QSAR models predict the biological activity of new or untested compounds based on their structural properties. This is particularly useful for prioritizing compounds for experimental testing in drug discovery. (46) Lead Optimization, QSAR can aid in lead optimization by suggesting structural modifications that are likely to improve a compound's activity, selectivity, or pharmacokinetic properties. QSAR models can also predict the toxicity of compounds, helping to identify potential safety concerns early in the drug development process. In high-throughput screening and virtual screening campaigns, QSAR models are employed to prioritize compounds from large libraries for experimental testing, saving time and resources.(47) QSAR complements other CADD techniques like molecular docking and pharmacophore modeling by providing quantitative insights into the relationships between chemical structure and activity. QSAR analysis relies heavily on the quality and relevance of input data. Data errors, or experimental variability can impact model accuracy (48) The selection of appropriate molecular descriptors and modeling techniques is crucial for model robustness and predictive power. QSAR models are often specific to a particular biological activity and may not be transferable to different targets or endpoints.(49)

STRUCTURE-BASED DRUG DESIGN (SBDD)

Structure-Based Drug Design (SBDD) is a highly effective approach in CADD that focuses on designing and optimizing pharmaceutical compounds based on detailed knowledge of the three-dimensional (3D) structure of a biological target, typically a protein receptor or enzyme. SBDD this structural information to understand molecular interactions at the atomic level and to guide the rational design of molecules with high binding affinity and specificity for the target(50)

SBDD starts with the selection of a biologically relevant target, often a protein associated with a disease or a key cellular process. Protein structures can be determined experimentally through X-ray crystallography, NMR spectroscopy, or cryoelectron microscopy. (51) Alternatively, homology modeling can be used to predict the 3D structure of a target based on known homologous protein structures. Once the target structure is available, the ligand binding site (active site) is identified and analyzed. This involves identifying amino acid residues, ions, or water molecules that play crucial roles in ligand binding.(52) Virtual screening is a key component of SBDD and involves the computational screening of large compound libraries to identify potential drug candidates. Molecular docking simulations are employed to predict how different ligands (compounds) interact with the target's binding site.(53) The goal is to calculate the binding affinity and binding mode of each ligand within the site. Scoring functions are used to rank ligands based on their predicted binding energies and interactions with the target. Compounds with the highest binding affinity (hits) identified through virtual screening are further analyzed and optimized.(54) Structural information from the docking simulations guides medicinal chemists in making informed modifications to the chemical structure of the lead compound to improve binding and other pharmacological properties. This iterative process is known as lead optimization. Promising compounds resulting from SBDD are synthesized and subjected to experimental validation, including in vitro and in vivo assays, to confirm their binding affinity and biological activity. Experimental data is used to refine and validate the SBDD-derived models and predictions. SBDD also helps assess the drug ability of a target. Some targets may have binding sites that are difficult to target with small molecules due to their size, shape, or flexibility. (55) Drug ability assessment aids in target selection for drug discovery efforts .SBDD has been instrumental in the discovery of numerous drugs and therapeutics across various disease areas, including cancer, infectious diseases, and neurological disorders. SBDD is often used in conjunction with FBDD, where smaller, fragment-sized molecules are designed to bind to specific regions within the binding site. These fragments can be later linked and expanded into larger compounds. SBDD can be used to design molecules that interact with multiple targets, allowing for the development of multi-targeted therapies.(56)

MOLECULAR DOCKING

Molecular docking is a critical computational technique in CADD that simulates the interaction between small molecules and biological target molecules usually protein) to predict their binding modes and binding affinities. Docking plays a pivotal role in the discovery and design of new drugs, as it helps researchers understand how potential drug candidates interact with their target proteins at the atomic level.(57) The primary goal of molecular docking is to predict how a ligand binds to a specific binding site on a target molecule. This information is crucial for understanding the mechanism of action and for designing or optimizing drugs. The ligand is the small molecule of interest, such as a drug candidate or a chemical compound. It is docked into the binding site of the target protein. The target protein is often a biomolecule related to a disease or a cellular process. (58) The 3D structure of the target protein is a prerequisite for molecular docking. Docking algorithms use scoring functions to evaluate the energetics of ligand-protein interactions. Scoring functions estimate the binding affinity and predict the stability of the ligand-protein complex. Prior to docking, both the ligand and the protein must be prepared. This involves adding hydrogen atoms, assigning charges, and optimizing the ligand and protein structures.(59) Docking software explores different conformations of the ligand to find the most favorable binding pose within the binding site. The ligand is systematically placed into the binding site of the protein. Various algorithms, such as Lamarckian Genetic Algorithm, Monte Carlo, or other stochastic methods, are used to search for energetically favorable binding poses. Scoring functions evaluate and rank the binding poses based on their predicted binding energies. The pose with the lowest energy is considered the most likely binding mode.(60)

Molecular docking is used to screen large compound libraries and identify potential drug candidates that bind strongly to the target of interest. These candidates are selected for further evaluation. Once lead compounds are identified, docking can guide chemical modifications to improve binding affinity, selectivity, and other pharmacological properties. (61) Docking can help design multi-targeted drugs that interact with multiple binding sites or proteins involved in a disease pathway. Molecular docking can provide insights into the mechanism of action of known drugs or compounds, shedding light on how they interact with their targets Docking can also be used to predict protein-protein interactions, which are crucial in many biological processes Docking results are highly dependent on the accuracy of the target protein's 3D structure.(62) If the structure is incorrect or lacks certain details, docking predictions may be less reliable .Scoring functions have limitations and may not always accurately predict binding affinities. Molecular dynamics simulations can complement docking by capturing the dynamic nature of ligand-protein interactions.(63)

MOLECULAR DYNAMICS

Molecular Dynamics (MD) is a crucial computational technique in the field of CADD. It plays a pivotal role in understanding the dynamic behavior of molecules at the atomic level, providing insights into the interactions between drugs and their biological targets.(64) MD simulations offer a unique and detailed perspective on how molecules move, interact, and change conformation over time, which is essential for rational drug design.MD simulations model the behavior of atoms and molecules over time by numerically solving the equations of motion. This allows researchers to observe how a drug molecule interacts with a biological target, such as a protein or an enzyme, in a dynamic and time-dependent manner.(65) This dynamic perspective is crucial because biological processes are inherently dynamic.MD simulations calculate the potential energy of a system based on the interactions between atoms and molecules. By evaluating energy terms like electrostatic interactions, van der Waals forces, and bonded terms researchers can gain insights into the stability and energetics of drug-target complexes. One of the strengths of MD is its ability to explore the conformational space of molecules.(66) It can reveal different conformations and binding modes of a drug within its target, which is essential for understanding the binding mechanism and optimizing drug candidates.MD simulations can include the effects of solvent molecules surrounding the drug and target. This is particularly important because biological processes occur in a solvent environment. MD helps researchers understand how solvent molecules influence drug binding and stability.(67) MD simulations can be used to predict and optimize the binding affinity of a drug for its target. By running simulations with various drug analogs or modifications, researchers can identify the most promising candidates with improved binding properties. Proteins are dynamic structures that can undergo conformational changes upon ligand binding.(68) MD simulations are valuable for studying protein flexibility and the induced-fit phenomenon, where a protein's structure adjusts to accommodate a ligand. This information is crucial for drug design.MD simulations can provide detailed information about the specific interactions between a drug and its target, such as hydrogen bonds, hydrophobic interactions, and salt bridges.(69) Understanding these interactions is essential for rational drug design. Advanced MD techniques, such as free energy calculations, can estimate binding affinities and predict the thermodynamics of ligand binding. These calculations can guide the selection of lead compounds and prioritize drug candidates. Molecular Dynamics is a powerful computational technique in CADD that allows

researchers to simulate and analyze the dynamic behavior of molecules.(70) It provides a comprehensive understanding of drug-target interactions, including the energetics, conformational changes, and solvent effects, which are essential for rational drug design. By combining MD simulations with other CADD approaches like virtual screening and structure-based design, researchers can accelerate the discovery and optimization of novel drug candidates with improved efficacy and safety profiles.(71)

CONCLUSION

Computer-Aided Drug Design has emerged as a transformative force in the field of drug discovery and development. Through the integration of computational techniques, chemistry, biology, and informatics, CADD has revolutionized the way pharmaceutical research is conducted. As we conclude our exploration of CADD, it becomes evident that this multidisciplinary approach has had a profound impact on the pharmaceutical industry and holds great promise for the future of healthcare. Traditional drug discovery often involved a high rate of failure. CADD has contributed to improved success rates by providing a rational and systematic approach to drug design. Computational tools allow researchers to make more informed decisions about which compounds to reducing the risk of late-stage clinical trial failures.

ACKNOWLEDGEMENTS

We would like to express our gratitude to all authors for their thoughtful contributions and collaborative spirit.

CONFLICT OF INTEREST

All authors declare that no conflict of interest.

FUNDING: Not applicable

ETHICS STATEMENT: Not applicable

REFERENCES

1. Leelananda SP, Lindert S. (2016). Computational methods in drug discovery. Beilstein J Org Chem. ;12:2694–718.
2. Shaker B, Ahmad S, Lee J, Jung C, Na D. (2021). *In silico* methods and tools for drug discovery. Comput Biol Med. 2021;137.
3. Van Ginneken B, Schaefer-Prokop CM, Prokop M. (2011). Computer-aided diagnosis: How to move from the laboratory to the clinic. Radiology. 261(3):719–32.
4. Nicolas FE, Lopez-Martinez AF. (2010). MicroRNAs in human diseases. Recent Patents DNA Gene Seq. ;4(3):142–54.
5. Sabe VT, Ntombela T, Jhamba LA, Maguire GEM, Govender T, Naicker T, et al.(2021). Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. Eur J Med Chem. 224.
6. Circular Dichroism Techniques: Biomolecular and Nanostructural Analyses- A Review - Ranjbar - 2009 - Chemical Biology & Drug Design - Wiley Online Library. Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1747-0285.2009.00847.x
7. Macalino SJY, Gosu V, Hong S, Choi S. (2015). Role of computer-aided drug design in modern drug discovery. Arch Pharm Res. 38(9):1686–701.
8. Fourches D, Muratov E, Tropsha A. (2010). Trust, but verify: On the importance of chemical structure curation in cheminformatics and QSAR modeling research. J Chem Inf Model. 50(7):1189–204.
9. Sander T, Freyss J, Von Korff M, Reich JR, Rufener C.(2009). OSIRIS, an entirely in-house developed drug discovery informatics system. J Chem Inf Model.49(2):232–46.
10. Bhattarai S, Kumar R, Nag S, Namasivayam V. (2022). Big Data in Drug Discovery. Mach Learn Syst Biol Genomics Heal. ;17–48.
11. Bjerrum EJ, Sattarov B. (2018). Improving chemical autoencoder latent space and molecular de novo generation diversity with heteroencoders. Biomolecules. ;8(4). 901-908
12. Mohammad HB, Khurshid A, Sudeep R, Jalaluddin MA, Mohd A, (2016). Mohammad HS, et al. Computer Aided Drug Design: Success and Limitations. Curr Pharm Des.22:572–81.
13. Young DW, Bender A, Hoyt J, McWhinnie E, Chirn GW, Tao CY, et al. (2008). Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol. 4(1):59–68.
14. Bender BJ, Gahbauer S, Luttens A, Lyu J, Webb CM, Stein RM, et al. (2021). A practical guide to large-scale docking. Nat Protoc.16(10):4799–832.
15. Sheridan RP, Kearsley SK.(2002). Why do we need so many chemical similarity search methods? Drug Discov Today. 7(17):903–11.
16. Wolber G, Dornhofer AA, Langer T. (2006). Efficient overlay of small organic molecules using 3D pharmacophores. J Comput Aided Mol Des. 20(12):773–88.

17. Hoque I, Chatterjee A, Bhattacharya S, Biswas R. (2017). An Approach of Computer-Aided Drug Design (CADD) Tools for In Silico Pharmaceutical Drug Design and Development. Int J Adv Res Biol Sci. ;4(2):60–71.
18. Hu Y, Stumpfe D, Bajorath J. (2016). Recent Advances in Scaffold Hopping Miniperspective. J Med Chem. ;60(4):1238–46.
19. Alvim-Gaston M, Grese T, Mahoui A, Palkowitz A, Pineiro-Nunez M, Watson I. (2014). Open Innovation Drug Discovery (OIDD): A Potential Path to Novel Therapeutic Chemical Space. Curr Top Med Chem. ;14(3):294–303.
20. Nantasenamat C, Isarankura-Na-Ayudhya C, Naenna T, Prachayasittikul V. (2020). A practical overview of quantitative structure-activity relationship. EXCLI J.8:74–88.
21. Agoni C, Olotu FA, Ramharack P, Soliman ME. (2020). Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say? J Mol Model.26(6). 1211-1219
22. Katsila T, Spyroulias GA, Patrinos GP, Matsoukas MT. (2016). Computational approaches in target identification and drug discovery. Comput Struct Biotechnol J.14:177–84.
23. Basile AO, Yahi A, Tatonetti NP. (2019). Artificial intelligence for drug toxicity and safety. Trends in pharmacological sciences. 1;40(9):624-35.
24. Yadav V, Reang J, Vinita, Tonk RK. (2022). Ligand-based drug design (LBDD). Comput Aided Drug Des From Ligand-Based Methods to Struct Approaches. ;57–99.
25. Loew GH, Villar HO, Alkorta I. (1993). Strategies for Indirect Computer-Aided Drug Design. Pharm Res An Off J Am Assoc Pharm Sci.10(4):475–86.
26. Dixon SL, Smondyrev AM, Rao SN. (2006). PHASE: A novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des.67(5):370–2.
27. 27. Ma DL, Chan DSH, Lee P, Kwan MHT, Leung CH.(2011). Molecular modeling of drug-DNA interactions: Virtual screening to structure-based design. Biochimie.93(8):1252–66.
28. Tan XF, Zhu SS, Wang RP, Chen Y Di, Show PL, Zhang FF, et al. (2021). Role of biochar surface characteristics in the adsorption of aromatic compounds: Pore structure and functional groups. Chinese Chem Lett. 32(10):2939–46.
29. 29. Baroni M, Cruciani G, Sciabola S, Perruccio F, Mason JS. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): Theory and application. J Chem Inf Model. 2007;47(2):279–94.
30. 30. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des. 2006;20(10–11):647–71.
31. 31. Kutlushina A, Khakimova A, Madzhidov T, Polishchuk P. Ligand-based pharmacophore modeling using novel 3D pharmacophore signatures. Molecules. 2018;23(12).
32. 32. Sanders MPA, McGuire R, Roumen L, De Esch IJP, De Vlieg J, Klomp JPG, et al. From the protein's perspective: The benefits and challenges of protein structure-based pharmacophore modeling. Medchemcomm. 2012;3(1):28–38.
33. 33. Thangapandian S, John S, Arooj M, Lee KW. Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design. PLoS One. 2012;7(4).
34. 34. Martin YC, Bures MG, Danaher EA, DeLazzer J, Lico I, Pavlik PA. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J Comput Aided Mol Des. 1993;7(1):83–102.
35. 35. Lu SH, Wu JW, Liu HL, Zhao JH, Liu KT, Chuang CK, et al. The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies. J Biomed Sci. 2011;18(1).
36. 36. Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: In vitro safety pharmacology profiling: An essential tool for successful drug development. Drug Discov Today. 2005;10(21):1421–33.
37. 37. Fagan WF, Lewis MA, Auger-Méthé M, Avgar T, Benhamou S, Breed G, et al. Spatial memory and animal movement. Ecol Lett. 2013;16(10):1316–29.
38. 38. van Gunsteren WF, Berendsen HJC. Computer Simulation of Molecular Dynamics: Methodology, Applications, and Perspectives in Chemistry. Angew Chemie Int Ed English. 1990;29(9):992–1023.
39. Ekins S, Mestres J, Testa B. (2007). *In silico* pharmacology for drug discovery: Methods for virtual ligand screening and profiling. Br J Pharmacol. 152(1):9–20.
40. Schneider P, Schneider G. (2016). De Novo Design at the Edge of Chaos: Miniperspective. J Med Chem.59:4077.
41. Chtita S, Belhassan A, Bakhouch M, Taourati AI, Aouidate A, Belaidi S, et al.(2021). QSAR study of unsymmetrical aromatic disulfides as potent avian SARS-CoV main protease inhibitors using quantum chemical descriptors and statistical methods. Chemom Intell Lab Syst. 210.
42. Poroikov V V., Filimonov DA, Ihlenfeldt WD, Gloriozova TA, Lagunin AA, Borodina Y V., et al. (2003). PASS biological activity spectrum predictions in the enhanced open NCI Database Browser. J Chem Inf Comput Sci. 43(1):228–36.
43. Mahlin D, Ponnambalam S, Heidarian Höckerfelt M, Bergström CAS. (2011). Toward in silico prediction of glass-forming ability from molecular structure alone: A screening tool in early drug development. Mol Pharm. 8(2):498–506.
44. Pastor M, Cruciani G, McLay I, Pickett S, Clementi S.(2000). GRid-INdependent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors. J Med Chem. ;43(17):3233–43.
45. Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M, et al. (2014). QSAR modeling: Where have you been? Where are you going to? J Med Chem4;57(12):4977–5010.

46. de Souza Neto LR, Moreira-Filho JT, Neves BJ, Maidana RLBR, Guimarães ACR, Furnham N, et al.(2020). *In silico* Strategies to Support Fragment-to-Lead Optimization in Drug Discovery. Front Chem. ;8.10-15
47. B.J. N, R.C. B, C.C. MF, J.T. MF, E.N. M, C.H. A. (2018). QSAR-based virtual screening: Advances and applications in drug discovery. Front Pharmacol [Internet].;9(NOV). Available from: http:// www.embase.com/search/results?subaction=viewrecord&from=export&id=L624900892%0Ahttp://dx.doi.org/ 10.3389/fphar.2018.01275
48. Cronin MTD, Richarz AN, Schultz TW. (2019). Identification and description of the uncertainty, variability, bias and influence in quantitative structure-activity relationships (QSARs) for toxicity prediction. Regul Toxicol Pharmacol. 106:90–104.
49. Cos P, Vlietinck AJ, Berghe D Vanden, Maes L.(2006). Anti-infective potential of natural products: How to develop a stronger in vitro "proof-of-concept." J Ethnopharmacol. 106(3):290–302.
50. Ooms F. (2012). Molecular Modelling and Computer Aided Drug Design. Examples of their Applications in Medicinal Chemistry. Curr Med Chem.7(2):141–58.
51. Kryshtafovych A, Moult J, Albrecht R, Chang GA, Chao K, Fraser A, et al. (2021). Computational models in the service of X-ray and cryo-electron microscopy structure determination. Proteins Struct Funct Bioinforma.89(12):1633–46.
52. Sun YJ, Rose J, Wang BC, Hsiao CD. (1998). The structure of glutamine-binding protein complexed with glutamine at 1.94 Å resolution: Comparisons with other amino acid binding proteins. J Mol Biol. ;278(1):219–29.
53. Pinzi L, Rastelli G. (2019). Molecular docking: Shifting paradigms in drug discovery. Int J Mol Sci. ;20(18).
54. Poli G, Martinelli A, Tuccinardi T. (2016). Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies. J Enzyme Inhib Med Chem. ;31:167–73.
55. Kalyaanamoorthy S, Chen YPP. (2011). Structure-based drug design to augment hit discovery. Drug Discov Today. 16(17–18):831–9.
56. Kabir A, Muth A. (2022). Polypharmacology: The science of multi-targeting molecules. Pharmacol Res. 176:106055. doi: 10.1016/j.phrs.2021.106055. Epub 2022 Jan 3. PMID: 34990865.
57. 57. Naqvi AAT, Mohammad T, Hasan GM, Hassan MI. (2019). Advancements in Docking and Molecular Dynamics Simulations Towards Ligand-receptor Interactions and Structure-function Relationships. Curr Top Med Chem. 18(20):1755–68.
58. Alberti S, Hyman AA. (2021). Biomolecular condensates at the nexus of cellular stress, protein aggregation disease and ageing. Nat Rev Mol Cell Biol. 22(3):196–213.
59. Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 27(3):221–34.
60. 60. Velec HFG, Gohlke H, Klebe G. (2005). Drug ScoreCSD-knowledge-based scoring function derived from small molecule crystal data with superior recognition rate of near-native ligand poses and better affinity prediction. J Med Chem. 48(20):6296–303.
61. 61. Ghosh S, Nie A, An J, Huang Z. (2006). Structure-based virtual screening of chemical libraries for drug discovery. Curr Opin Chem Biol. ;10(3):194–202.
62. Smith GR, Sternberg MJE. (2002). Prediction of protein-protein interactions by docking methods. Curr Opin Struct Biol.12(1):28–35.
63. Santos LHS, Ferreira RS, Caffarena ER. (2019). Integrating molecular docking and molecular dynamics simulations. Methods Mol Biol.2053:13–34.
64. Huang HJ, Yu HW, Chen CY, Hsu CH, Chen HY, Lee KJ, et al.(2010). Current developments of computer-aided drug design. J Taiwan Inst Chem Eng. 41(6):623–35.
65. Massoud TF, Gambhir SS.(2003). Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev.17(5):545–80.
66. Hamelberg D, Mongan J, McCammon JA. (2004). Accelerated molecular dynamics: A promising and efficient simulation method for biomolecules. J Chem Phys. 120(24):11919–29.
67. Padhi AK, Rath SL, Tripathi T. (2021). Accelerating COVID-19 Research Using Molecular Dynamics Simulation. J Phys Chem B.125(32):9078–91.
68. Gunasekaran K, Nussinov R. (2007). How Different are Structurally Flexible and Rigid Binding Sites? Sequence and Structural Features Discriminating Proteins that Do and Do not Undergo Conformational Change upon Ligand Binding. J Mol Biol.365(1):257–73.
69. Kumar R, Murugan NA, Srivastava V. (2022). Improved Binding Affinity of Omicron's Spike Protein for the Human Angiotensin-Converting Enzyme 2 Receptor Is the Key behind Its Increased Virulence. Int J Mol Sci. 23(6).90-97
70. Rathod S, Bhande D, Pawar S, Gumphalwad K, Choudhari P, More H. (2023). Identification of Potential Hits against Fungal Lysine Deacetylase Rpd3 via Molecular Docking, Molecular Dynamics Simulation, DFT, In-Silico ADMET and Drug-Likeness Assessment. Chem Africa. 20 (1);10-15
71. Wu K, Karapetyan E, Schloss J, Vadgama J, Wu Y.(2023). Advancements in small molecule drug design: A structural perspective. Drug Discov Today.28(10).

CITATION OF THIS ARTICLE

Saurabh D, Tejas N, Mahesh S, Kiran D, Krushna D. From Code to Cure: Advancing Drug Discovery with Computer-Aided Design. Bull. Env.Pharmacol. Life Sci., Vol 13 [1] December 2023: 308-315